Hims & Hers Health (HIMS) legal chief sells 4,651 shares under plan

Rhea-AI Filing Summary

Hims & Hers Health, Inc. Chief Legal Officer Boughton Soleil sold 4,651 shares of Class A common stock in an open-market transaction. The shares were sold at an average price of $15.21 per share. After this sale, Soleil continues to hold 440,972 shares directly. The transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted on November 18, 2025, indicating it was scheduled in advance rather than decided at the time of sale.

Insider Trade Summary

Net Seller: 4,651 shares ($70,742)

Net Sell 1 txn

Insider Boughton Soleil

Role Chief Legal Officer

Sold 4,651 shs ($71K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	4,651	$15.21	$71K

Holdings After Transaction: Class A Common Stock — 440,972 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boughton Soleil

(Last) (First) (Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO CA 94123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/27/2026		S(1)		4,651	D	$15.21	440,972	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025 by the Reporting Person.

Remarks:

	/s/ Kimberly Mather, Attorney-in-Fact for Soleil Boughton	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Hims & Hers Health (HIMS) report for Boughton Soleil?

Hims & Hers Health reported that Chief Legal Officer Boughton Soleil sold 4,651 shares of Class A common stock. The sale was executed in the open market at an average price of $15.21 per share, under a pre-arranged Rule 10b5-1 trading plan.

How many HIMS shares did the Chief Legal Officer sell and at what price?

The Chief Legal Officer sold 4,651 Hims & Hers Health Class A shares at an average price of $15.21. This was an open-market transaction and part of an established Rule 10b5-1 trading plan, rather than an ad hoc sale decision.

How many Hims & Hers Health (HIMS) shares does Boughton Soleil hold after the sale?

Following the reported sale, Boughton Soleil directly holds 440,972 shares of Hims & Hers Health Class A common stock. This remaining position reflects ownership after disposing of 4,651 shares in an open-market transaction conducted under a Rule 10b5-1 plan.

Was the HIMS insider stock sale by Boughton Soleil under a Rule 10b5-1 plan?

Yes. The filing states the sales were executed under a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans allow insiders to pre-schedule trades, helping separate personal trading decisions from day-to-day market or company developments.

What is the nature of ownership for the HIMS shares held by Boughton Soleil?

The filing identifies Boughton Soleil’s ownership of Hims & Hers Health shares as direct. After the open-market sale of 4,651 Class A shares at $15.21, Soleil directly owns 440,972 shares, with no indication in the footnotes of separate entities holding these reported shares.